OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) (“Avivagen” or “Corporation”), a world leader in natural alternatives to antibiotics with its OxC-beta™ technology, is pleased to announce that it has received a new purchase order for its OxC-beta™ Livestock product. This order represents a new customer in a new jurisdiction and also demonstrates the continued expansion of OxC-beta™ Livestock into new markets. The client, who is based in Asia, has asked Avivagen for confidentiality regarding their first order.
“This is further evidence that our strategic plan to increase acceptance, adoption and ultimately sales of OxC-beta Livestock is gaining critical momentum. We already have a significant foothold in Asia and this new partner in a new jurisdiction reflects our ability to execute on specific tactics in our growth plan - to open new markets and develop new partners in those same areas,” said Chairman and Interim CEO Kym Anthony. “We hope this initial order is just the start of a long and mutually beneficial relationship with our new Asian partner.”
About Avivagen
Avivagen is a life sciences corporation
focused on developing and commercializing products for livestock,
companion animal and human applications that, by safely supporting
immune function, promote general health and performance. It is a public
corporation traded on the TSX Venture Exchange under the symbol VIV and
is headquartered in Ottawa, Canada, based in partnership facilities of
the National Research Council of Canada and Charlottetown, Prince Edward
Island. For more information, visit www.avivagen.com.
The contents of the website are expressly not incorporated by reference
in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s
OxC-beta™ technology is derived from Avivagen discoveries about
carotenoids, compounds that give certain fruits and vegetables their
bright colours, and is a non-antibiotic means of maintaining optimal
health and growth. OxC-beta™ Livestock is a proprietary product shown to
be effective and economic in replacing the antibiotics commonly added to
livestock feeds
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements
This news release includes
certain forward-looking statements that are based upon the current
expectations of management. Forward-looking statements involve risks and
uncertainties associated with the business of Avivagen and the
environment in which the business operates. Any statements contained
herein that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions “aim”,
“anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”,
“expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”,
“possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”,
“will”, “would” and similar expressions. Statements about OxC-beta’s
ability to replace antibiotics commonly added to livestock feeds or to
fulfill the global mandate to remove in-feed antibiotics as growth
promoters, the possibility for continued sales momentum for Avivagen’s
products, the possibility for additional new partners in Asia and the
possibility for future orders from this customer set out in this news
release are forward-looking statements. These forward-looking statements
are subject to a number of risks and uncertainties that could cause
actual results or events to differ materially from current expectations.
For instance, Avivagen’s products may not gain market acceptance or
regulatory approvals necessary to fulfill the global mandate to remove
in-feed antibiotics as growth promoters, Avivagen’s sales may not
continue to grow, the sales to this customer may not lead to or be
indicative of the possibility for future sales to new partners in Asia
and this customer is under no obligation to make additional orders from
Avivagen. Please refer to Avivagen’s most recent annual information form
available at www.SEDAR.com
for a non-exhaustive discussion of risk factors facing Avivagen’s
business and the foregoing forward looking statements. Except as
required by law, Avivagen assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2019 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.